**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 75421

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Soluble factors secreted by human Wharton’s jelly mesenchymal stromal/stem cells exhibit therapeutic radioprotection: A mechanistic study with integrating network biology**

Maurya DK *et al*. Soluble factors secreted by hWJ-MSCs

Dharmendra Kumar Maurya, Mayuri Bandekar, Santosh Kumar Sandur

**Dharmendra Kumar Maurya, Mayuri Bandekar, Santosh Kumar Sandur,** Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai 400085, Maharashtra, India

**Dharmendra Kumar Maurya, Santosh Kumar Sandur,** Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India

**Mayuri Bandekar,** University of Mumbai, Kalina, Mumbai 400098, India

**Author contributions:** Maurya DK contributed to conceptualization, experimentation, data analysis, and writing of the manuscript; Bandekar M contributed to experimentation; Sandur SK contributed to manuscript correction and finalization; All authors have read and approve the final manuscript.

**Corresponding author: Dharmendra Kumar Maurya, BSc, MSc, PhD,** Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, 3-82-S, A-block, Modular Laboratory, Mumbai 400085, Maharashtra, India. [dkmaurya@barc.gov.in](mailto:dkmaurya@barc.gov.in)

**Received:** January 28, 2022

**Revised:** March 25, 2022

**Accepted: May 8, 2022**

**Published online:**

**Abstract**

BACKGROUND

Human Wharton’s jelly-derived mesenchymal stromal/stem cells (hWJ-MSCs) have gained considerable attention in their applications in cell-based therapy due to several advantages offered by them. Recently, we reported that hWJ-MSCs and their conditioned medium have significant therapeutic radioprotective potential. This finding raised an obvious question to identify unique features of hWJ-MSCs over other sources of stem cells for a better understanding of its radioprotective mechanism.

AIM

To understand the radioprotective mechanism of soluble factors secreted by hWJ-MSCs and identification of their unique genes.

METHODS

Propidium iodide staining, endogenous spleen colony-forming assay, and survival study were carried out for radioprotection studies. Homeostasis-driven proliferation assay was performed for *in vivo* lymphocyte proliferation. Analysis of RNAseq data was performed to find the unique genes of WJ-MSCs by comparing them with bone marrow mesenchymal stem cells, embryonic stem cells, and human fibroblasts. Gene enrichment analysis and protein-protein interaction network were used for pathway analysis.

RESULTS

Co-culture of irradiated murine splenic lymphocytes with WJ-MSCs offered significant radioprotection to lymphocytes. WJ-MSC transplantation increased the homeostasis-driven proliferation of the lymphocytes. Neutralization of WJ-MSC conditioned medium with granulocyte-colony stimulating factor antibody abolished therapeutic radioprotection. Transcriptome analysis showed that WJ-MSCs share several common genes with bone marrow MSCs and embryonic stem cells and express high levels of unique genes such as interleukin (*IL*)*1-α*, *IL1-β*, *IL-6*, *CXCL3*, *CXCL5*, *CXCL8*, *CXCL2*, *CCL2*, *FLT-1*, and *IL-33*. It was also observed that WJ-MSCs preferentially modulate several cellular pathways and processes that handle the repair and regeneration of damaged tissues compared to stem cells from other sources. Cytokine-based network analysis showed that most of the radiosensitive tissues have a more complex network for the elevated cytokines.

CONCLUSION

Systemic infusion of WJ-MSC conditioned media will have significant potential for treating accidental radiation exposed victims.

**Key Words:** Radioprotection; Mesenchymal stem cells; Wharton’s jelly-derived mesenchymal stromal/stem cells; Cytokines; Granulocyte-colony stimulating factor; Network biology

Maurya DK, Bandekar M, Sandur SK. Soluble factors secreted by human Wharton’s jelly mesenchymal stromal/stem cells exhibit therapeutic radioprotection-a mechanistic study with integrating network biology. *World J Stem Cells* 2022; In press

**Core Tip:** This study showed the potential role of cytokine granulocyte-colony stimulating factor in therapeutic radioprotection. Transcriptome analysis showed that Wharton’s jelly-derived mesenchymal stromal/stem cells (WJ-MSCs) have a unique set of genes compared to bone marrow MSCs and embryonic stem cells. WJ-MSCs secrete several cytokines that promote cellular pathways that handle tissue repair and regeneration.

**INTRODUCTION**

Exposure of mice to high doses of gamma radiation causes acute radiation syndrome (ARS), which includes damage to hematopoietic, gastrointestinal, and neurovascular systems depending on the dose. Currently, extensive progress has been made to understand the molecular players leading to ARS and therapeutic options. Several agents have been reported to protect mice from ARS, which include thiol-containing compounds, phytochemicals[1-3], and several cytoprotective cytokines and growth factors [interleukin (IL)-1, IL-6, tumor necrosis factor-α, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor], *etc*[4-6].

Stem cell therapy is one of the promising strategies for the amelioration of ARS because of its ability to regenerate by sensing the damage. Mesenchymal stromal/stem cells (MSCs) are one such type of cells that have the potential for clinical applications. They are easy to culture and possess low immunogenicity, high regenerative potential, multilineage differentiation abilities, and potent antiapoptotic and immunosuppressive effects[7]. Several reports have shown the ability of MSCs to repair various tissue injuries induced by radiation and other stressors[8-12]. The mechanism of action to prevent radiation-induced tissue injury by MSCs could be paracrine secretion of several soluble factors[13,14]. Various paracrine factors secreted by MSCs include cytokines, chemokines, pro-survival factors, and growth factors[15-19]. All these properties of the MSCs may help in recovery from hematopoietic and gastrointestinal tract injury after radiation exposure.

The therapeutic potential of bone marrow MSCs (BM-MSCs) against radiation injury has been well documented in several experimental studies[20-24]. Lange *et al*[23] showed that a protective response was evoked in combating inflammatory events post-radiation exposure after systemic administration of MSCs[23]. Another study by Chang *et al*[11] showed protection against whole body irradiation (WBI)-induced damage to the intestinal mucosa by enhancing angiogenesis and chemotaxis after bone marrow transplantation[11]. Existing evidence shows that MSCs “home in” to bone marrow or other injured tissues and secrete different soluble factors that help in the recovery of radiation-induced hematopoietic damage *via* induction of hematopoietic stem/progenitor cell division and differentiation[23-25]. The trophic factors (granulocyte-macrophage colony-stimulating factor, thrombopoietin, and stem cell factor) secreted by MSCs can modulate the hematopoietic stem cell niche thereby rescuing endogenous hematopoiesis[23,25].

Stem cells isolated from Wharton’s jelly of the umbilical cord (WJ-MSCs) are a unique source of MSCs. These cells did not induce any adverse effects or teratoma formation in the recipients and are hence considered safe[26]. WJ-MSCs exhibit reduced immunogenicity[27] as compared to other MSC types. WJ-MSCs have low expression of costimulatory ligands, which otherwise can stimulate immune responses[28]. Interestingly, WJ-MSCs are known to express human leukocyte antigen G, which helps in the expansion of immunosuppressive regulatory T cells. Recently, our laboratory has shown the radioprotective potential of human WJ-MSCs and conditioned media collected from culturing WJ-MSCs against ionizing radiation-induced mortality in mice[8,29].

In the present study, we have established the involvement of cytokine G-CSF in the observed radioprotection offered byhuman WJ-MSC-conditioned medium (WJ-MSC-CM). We have also constructed the cytokine network using an experimentally determined list of the cytokines secreted in mouse blood serum 4 h after human WJ-MSC transplantation in the mice. Our study showed that the protein-protein interaction (PPI) network constructed using cytokines is more complex in the radiosensitive tissues as compared to other tissues such as muscle. Our transcriptome analysis showed that WJ-MSCs preferentially modulated several cellular pathways and processes that are responsible for the repair and regeneration of damaged tissues.

**MATERIALS AND METHODS**

***Chemicals and reagents***

MSC expansion medium, RPMI-1640 medium, fetal bovine serum (FBS), and antibiotic–antimycotic mixture were purchased from Hi-Media Pvt (Mumbai, India). MSC qualified FBS was purchased from Thermo Fischer Scientific. Propidium iodide (PI), ribonuclease A, and Triton X-100 were purchased from Sigma Chemical Co. (St Louis, MO, United States). Hoechst 33342 and carboxyfluorescein diacetate succinimidyl ester (CFSE) was procured from Molecular Probes (Eugene, OR, United States). Anti-G-CSF antibody was procured from R&D Systems (Minneapolis, MN, United States). All other chemicals used were of analytical grade and were procured from local manufacturers.

***Isolation and characterization of WJ-MSCs***

Ethical approval for isolation of WJ-MSCs was obtained from the Institutional ethical review board at Bhabha Atomic Research Centre Hospital, Mumbai, India (project numbers IC-SCRBARC/2018/2 and BARCHMEC/14). Human umbilical cords were freshly collected soon after the delivery of a full-term infant by cesarean section from the donor after obtaining written consent[8]. WJ-MSCs were isolated from the umbilical cord and characterized as described earlier[8]. They were cultured in MSC expansion medium added with 20% MSC qualified FBS, and 1% antibiotic-antimycotic mixture.

***Animal maintenance***

Ten- to twelve-week-old male Swiss mice weighing approximately 20-25 g were selected from an inbred group maintained under standard condition of temperature (25 ± 2 ºC) and reared in the animal house of the Bhabha Atomic Research Centre. The guidelines issued by the Institutional Animal Ethics Committee of Bhabha Atomic Research Centre, Government of India (project No. BAEC/15/18 dated April 2018) regarding maintenance and dissection of animals were strictly followed.

***Preparation of WJ-MSC-CM***

WJ-MSCs (5 × 104) were cultured in 1 mL WJ-MSC complete media for 24 h in a 24-well plate. After incubation, media was harvested, centrifuged at 1000 rpm for 2 min, and then filtered through a 0.22 μm sterile syringe filter. Conditioned media was kept in the ultra-deep freezer in aliquots and thawed as and when required.

***Co-culture of WJ-MSCs/CM with irradiated murine splenic lymphocytes***

To study the radioprotective property of WJ-MSCs *in vitro*, different numbers of WJ-MSCs (6.25 × 103, 12.5 × 103, and 25 × 103) were seeded in a 24-well cell culture plate. The next day 2 Gy gamma-irradiated murine splenic lymphocytes were co-cultured with pre-seeded WJ-MSCs. Splenocytes were incubated for 24 h in complete RPMI-1640 medium (RPMI-1640 medium supplemented with 10% FBS and 100 units/mL penicillin/100 μg/mL streptomycin). To study the radioprotective property of WJ-MSC-CM, irradiated lymphocytes suspended in RPMI-1640 were mixed with normal medium or WJ-MSC-CM in a 1:1 ratio and cultured for 24 h with 10% FBS. Cells were then washed with PBS and stained with 1 mL of PI solution (0.5 μg/mL PI, 10 μg/mL ribonuclease A, 0.1% sodium citrate, and 0.1% Triton X-100) overnight. Cells were subjected to flow cytometry, and the data was analyzed using FlowJo v10 software. The pre-G1 population in the histogram represented apoptotic cells.

***Neutralization of WJ-MSC-CM***

WJ-MSC-CM (24 h cultured) was treated with 5 μg/mL of human G-CSF neutralizing antibody. This conditioned media was incubated at 37 °C for 2 h. The G-CSF neutralized CM (200 μL) was infused to lethally irradiated mice to investigate the role of G-CSF in therapeutic radioprotection[8].

***Spleen index and endogenous spleen colony formation***

Endogenous spleen colony formation is considered a gold standard assay for the demonstration of radioprotection. To study the effect of WJ-MSC-CM or G-CSF neutralized WJ-MSC-CM on radiation-induced reduction in spleen index and endogenous spleen colony formation, mice were divided into four groups: Control, 6 Gy WBI, 6 Gy WBI + WJ-MSC-CM, and 6 Gy WBI + WJ-MSC-CM neutralized with G-CSF. Mice were exposed to 6 Gy WBI[8] and injected with 200 μL WJ-MSC-CM or WJ-MSC-CM neutralized with G-CSF 24 h after radiation exposure. Mice were sacrificed on day 15, and weights of mice and spleens were recorded. Spleens were then fixed in Bouin’s solution. Spleen index was calculated by taking the ratio of spleen weight to mouse weight. The spleen colony forming units were counted as macroscopic colonies formed on the surface of the spleen as a result of the proliferation of surviving BM stem/progenitor cells.

***Survival study***

For studying the effect of WJ-MSC-CM infusion on the survival of mice, 8.5 Gy dose of radiation was selected based on our previous study[8]. For the survival study, mice were randomly divided into the following experimental groups: (1) Control: PBS alone; (2) 8.5 Gy WBI; (3) 8.5 Gy WBI + 24 h post-irradiation WJ-MSC-CM; and (4) 8.5 Gy WBI + 24 h post-irradiation WJ-MSC-CM neutralized with anti-G-CSF. The day of whole-body exposure was considered as day 0. WJ-MSC-CM or WJ-MSC-CM neutralized with anti-G-CSF (200 μL) were systemically infused through the lateral tail vein. Mice were monitored daily for 30 d.

***Enumeration of homeostasis-driven proliferation of lymphocytes***

To perform homeostasis-driven proliferation, lymphopenia was induced in mice by exposing them to 6 Gy WBI and keeping them for 24 h. Further, CFSE (20 μM) labeled splenic lymphocytes (6 × 106 cells) were infused into lymphopenic mice with or without WJ-MSCs through the lateral tail vein. Each group consisted of four mice. Spleens were collected 96 h after injection. Spleen index was calculated by recording spleen weight and mice weight. Samples (250000 lymphocytes) from each group were acquired on a flow cytometer to enumerate the frequency of donor cells and monitor their cell proliferation.

***Analysis of transcriptome data in stem cells derived from different sources***

The raw data for different sources of stem cells were downloaded from the GEO database {GSE20124 and GSE48022 having GEO accession No. GSM1165510, GSM1165511 (WJ-MSCs); GSM503594, GSM503595 [embryonic stem cells (ESCs)]; GSM1165505, GSM1165506 (BM-MSCs); GSM503604, GSM503605 (Fibroblast), and platform Affymetrix Human Genome U133 plus 2.0 Array in CEL format} and analyzed using transcriptome analysis console (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, United States) for normalization of signal intensity, quality control, and statistical analysis. The differentially expressed genes in WJ-MSCs, BM-MSCs, and ESCs were compared with the fibroblasts using transcriptome analysis console. Further, *t*-test, Multiple Testing Corrections, and False Discovery Rate Prediction were employed to calculate the significance of differentially expressed genes. A threshold of 5-fold difference in gene expression between different stem cells compared to fibroblasts with a *P* < 0.05 was used for statistical significance.

***Gene enrichment analysis***

The data obtained from the transcriptome analysis console was utilized to assess the biological significance. BiNGO plugin of Cytoscape was used for assigning specific biological function, molecular function, and functional pathways for genes that were enriched among the upregulated genes[30]. The list of genes was statistically assessed by gProfiler using the following settings: Organism-*Homo sapiens*, statistical domain scope-Only annotated genes, significant threshold-Benjamini Hochberg FDR, and threshold-0.05[31].

***PPI network and construction of functional modules for selected cytokines/chemokines***

For creating PPI, a list of the cytokines elevated in mouse serum at 4 h post-WJ-MSC transplantation were obtained from our previous study[8]. A PPI network was constructed for these cytokines using Cytoscape (Ver 3.7.1). This constructed network was further extended using the STRING database. The Molecular Complex Detection was used to select modules of the PPI network with the following parameters: Degree cutoff = 2, node score cutoff = 0.2, core = 2, and max. depth = 100. Molecular Complex Detection encompasses an automated algorithm that detects densely connected regions in PPI networks that may represent molecular complexes. Further, BiNGO plugin of Cytoscape was used to obtain the biological significance of the predicted modules.

***Statistical analysis***

All the graphs were made using mean ± standard error using Microsoft Excel. Cellular data were analyzed for multiple comparison with Tukey-Kramer post-hoc test using KyPlot 5 statistical software (KyensLab Inc, Tokyo, Japan) with a statistical significance set at a*P* < 0.05 and b*P* < 0.001. For the survival study, Kaplan–Meier’s estimate of lifetime analysis was done using GraphPad Prism 5 software (GraphPad software, Inc., La Jolla, CA, United States). The difference between the estimated survival times of the two groups was evaluated by the log-rank test. The statistical significance of the log-rank test was considered if *P* < 0.05 according to χ2 distribution. c*P* < 0.0001.

**RESULTS**

***Co-culture of irradiated splenic lymphocytes with WJ-MSCs protected against radiation-induced cell death***

*In vitro* therapeutic potential of WJ-MSCs was evaluated using a co-culture study. Our study showed that when irradiated lymphocytes were co-cultured with a different number of pre-cultured WJ-MSCs for 24 h that they offered protection to lymphocytes as monitored by PI staining (Figure 1A). The extent of protection increased with an increasing number of WJ-MSCs. Subsequently, WJ-MSC-CM was added to irradiated lymphocytes, and cell death was measured using the PI assay. It was found that WJ-MSC-CM offered therapeutic protection against radiation-induced apoptosis in lymphocytes (Figure 1B). The results showed that WJ-MSCs offered protection to irradiated lymphocytes by secreting certain soluble mediators that may help in repair.

***Infusion of WJ-MSC-CM neutralized with anti-G-CSF diminished the protective effect***

Our previous findings showed that infusion of WJ-MSC-CM to lethally irradiated mice protected against mortality[8]. In the present study, infusion of conditioned media 24 h post-irradiation (6 Gy) led to better recovery in spleen index and endogenous spleen colony formation (Figure 2A and B). However, when WJ-MSC-CM was neutralized with anti-G-CSF and infused in irradiated mice, the protective effect of WJ-MSC-CM diminished as compared to mice that were injected with non-neutralized WJ-MSC-CM. Further, when non-neutralized WJ-MSC-CM was injected to lethally irradiated mice (8.5 Gy), it offered about 43% protection against mortality as compared to irradiated mice administered with WJ-MSC-CM neutralized with G-CSF (Figure 2C). It was also observed that surviving mice in the WJ-MSC-CM group recovered from WBI-induced morbidity (Figure 2D). These findings show that cytokine/growth factor G-CSF may be one factor responsible for the observed radioprotection offered by WJ-MSC-CM.

***Transplantation of WJ-MSCs increased homeostasis-driven proliferation of lymphocytes***

Transplantation of WJ-MSCs along with CFSE labeled lymphocytes into lymphopenic mice resulted in a higher frequency of CFSE positive lymphocytes in the host as compared to mice injected with CFSE labeled lymphocytes alone (Figure 3A and B). Further, these CFSE-labeled lymphocytes divided more times in the host when injected along with WJ-MSCs as compared to mice infused with CFSE labeled lymphocytes alone (Figure 3C and D). Figure 3E shows that the spleen index was higher in lymphopenic mice injected with lymphocytes along with WJ-MSCs as compared to mice that received only lymphocytes. These results indicated that WJ-MSCs or some of the soluble factors secreted by them may be helping in faster recovery from radiation-mediated injury.

***Transcriptome profile of different types of stem cells***

Our previous report[8] and the present findings have clearly shown that WJ-MSCs have distinct advantages over other stem cells like BM-MSCs and ESCs in ameliorating radiation injury. Hence, we wanted to understand the unique genes that are expressed by WJ-MSCs as compared to other stem cells and fibroblasts. For this purpose, gene expression data related to different stem cells were downloaded from the GEO database. Gene expression analysis was carried out by setting- gene-level fold change < -5 or > 5 and gene-level *P* < 0.05 (Anova method-Bayes). From Figure 4A, WJ-MSCs, BM-MSCs, and ESCs have 508, 553, and 2596 differentially expressed basal genes as compared to dermal fibroblasts, respectively. Among these, the number of downregulated genes was more. Interestingly, when WJ-MSCs were compared with BM-MSCs, 732 genes were differentially expressed, out of which 518 genes were upregulated, and 214 genes were downregulated in the WJ-MSCs. In contrast, when WJ-MSCs were compared with ESCs, 2701 genes were differentially expressed, out of which 1345 genes were upregulated, and 1356 genes were downregulated. On the other hand, when BM-MSCs were compared with the ESCs, 2900 genes were differentially expressed, out of which 1093 genes were upregulated in BM-MSCs, and 1807 genes were downregulated. Figure 4B shows the percentage of differentially expressed genes in WJ-MSCs when compared with fibroblasts, BM-MSCs, or ESCs, respectively. Supplementary Table 1 shows the list of the differentially expressed genes that are unique to WJ-MSCs. It is clear from Supplementary Table 1 that most of the differentially expressed genes of WJ-MSCs are different interleukins, growth factors (such as G-CSF), chemokines, various adhesion molecules, stemness markers, and many more that have a significant role in tissue regeneration and repair. Some of the highly upregulated and downregulated genes of the WJ-MSCs are plotted as shown in Figure 5.

***Gene enrichment analysis for unique genes of WJ-MSCs***

To explore the biological function of these identified unique genes of WJ-MSCs, gene enrichment analysis was performed using gProfiler for their gene ontology and functions. Supplementary Table 2 shows the gene ontology of unique genes from WJ-MSCs analyzed using gProfiler. A total of 32 biological processes were found to be influenced by these genes. Some of the functions of these genes are involved in the multicellular organismal process, positive regulation of macromolecule metabolic process, positive regulation of nitrogen compound metabolic process, positive regulation of the biological process, positive regulation of the metabolic process, and cytokine response. Some key molecular functions identified were cytokine activity, signaling receptor activator activity, receptor-ligand activity, cytokine receptor binding, molecular function regulator, and growth factor receptor binding. These genes belong to different cellular compartments like the extracellular matrix, extracellular space, and cell surface. To further understand how these differentially expressed genes influence the function of WJ-MSCs, we used prior knowledge of biological pathways reported in the literature. Figure 6 shows two of the major signaling pathways, cytokines, and inflammatory response pathway, and nuclear factor kappa B survival pathway, which regulates cell survival and death.

***PPI network and their cluster analysis***

Our previous findings showed that CM from cultured WJ-MSCs or serum collected from WJ-MSC-infused mice contained several cytokines, chemokines, and growth factors[8]. The information obtained from serum samples was used to construct an expanded PPI network (Figure 7A). When this PPI was analyzed for their tissue specificity, most of the radiosensitive tissues such as blood, bone marrow, intestine, and spleen show a more complex network as compared to the radio-resistant tissues such as skin, liver, and muscles (Figure 7B) indicating that the WJ-MSC-secreted cytokines may play a major role in the radiosensitive tissues compared to radio-resistant tissues. When the extended cytokine PPI was subjected to cluster analysis using Molecular Complex Detection, six distinct clusters were obtained. These clusters were analyzed for their functions and found that they were responsible for the modulation of the immune system and related functions (Figure 8).

**DISCUSSION**

Stem cell-based therapy is receiving significant attention in the field of regenerative medicine for treating various disorders and injuries[32]. During unplanned radiation exposure (such as radiation accidents), significant tissue damage is observed, and if not repaired/regenerated it can develop into ARS. To avoid ARS, regenerative therapy will be a good therapeutic option. In the past, the therapeutic potential of BM-MSCs for radioprotection has been demonstrated in several experimental studies[20-24]. The first case of human cord blood transfusion [locus-mismatched, unrelated human umbilical cord blood (hUCB) transfusion] to a lethally irradiated 39-year-old male exposed with neutrons to 8-10 Gy in the uranium-processing plant was documented in a radiation accident in Tokai, Japan in 1999, and he lived for 210 d[33]. Azzam *et al*[34] showed that combinatorial administration of hUCB cells with an antibiotic (Levaquin) showed recovery from hematopoietic and gastrointestinal tract syndromes in lethally irradiated mice[34].

WJ is another alternate source of MSCs and are safe compared to other sources due to no adverse effects or teratoma formation in the recipients[26]. WJ-MSCs lack costimulatory ligands, which otherwise can activate robust immune responses in the host[28]. In addition, preclinical studies have shown anti-tumor activity of WJ-MSCs[35-38]. Recently, we have shown that infusion of WJ-MSCs either 4 h or 24 h post-irradiation significantly protected against lethal irradiation[8]. We also demonstrated that infusion of WJ-MSC-CM offered therapeutic radioprotection. The possible mechanism by which WJ-MSCs offered radioprotection could be *via* secreting cytoprotective cytokines such G-CSF, IL-6, and Nrf-2[8]. G-CSF has received the Food and Drug Administration approval for the treatment of myelosuppression induced by radiation during radiological incidents/accidents[39,40]. Shim *et al*[41] showed that hUCB-MSC treatment significantly elevated the number of peripheral leukocyte counts in irradiated mice. They also reported that treatment with hUCB-MSCs was more effective than G-CSF treatment in supporting the proliferation of various cells in the bone marrow[41].

The current study explored the possible mechanism by which WJ-MSCs were offering therapeutic radioprotection using network biology. Our findings showed that the co-culture of WJ-MSCs with irradiated lymphocytes led to protection against radiation-induced cell death in lymphocytes (Figure 1). The observed radioprotection could be due to the release of certain soluble mediators such as radioprotective cytokines, which other investigators had earlier reported[42]. A homeostasis-driven proliferation study showed that infusion of WJ-MSCs along with lymphocytes into lymphopenic mice led to increased lymphocyte division as compared to the group where lymphocytes alone were injected (Figure 3). We also observed an improved spleen index in these mice. This study indicated that WJ-MSCs alone or the soluble factors secreted by them may be helping the infused lymphocytes to survive and proliferate in a lymphopenic environment. These factors may be helping the host lymphocytes to survive radiation-induced death, which in turn can protect against opportunistic infections in irradiated mice.

Our earlier results have shown that WJ-MSCs homed to the radiosensitive tissues in irradiated mice[8]. Thus, the infused WJ-MSCs after reaching the target site favor the repair of damaged tissues and alter the microenvironment similar to other MSCs by secreting different cytokines and growth factors[42]. The experiments carried out using CM of WJ-MSCs also showed a survival benefit to lethally irradiated mice. Interestingly, when this CM was neutralized with an anti-G-CSF antibody, WJ-MSC-CM failed to protect mice against radiation-induced mortality. This finding corroborates well with the hypothesis that WJ-MSCs might be secreting radioprotective cytokines in the observed radioprotection. However, administration of WJ-MSC-CM to lethally irradiated mice offered only about 40% protection indicating that other mechanisms are also playing a role in WJ-MSC-mediated radioprotection.

Alternatively, the concentration of G-CSF present in the WJ-MSC-CM may not be equivalent to G-CSF secreted by infused WJ-MSCs *in vivo*. It is well known that tissues/organs like bone marrow, spleen, and gastrointestinal tract where there is active cell division taking place are highly sensitive to radiation-induced cell death. The cytokine/chemokine-based network analysis showed that they are more complex in the radiosensitive tissues as compared to radio-resistant tissues indicating their role in tissue radioprotection.

Inflammatory response during infection that offers a protective mechanism requires coordination among various types of immune cells. After exposure to lethal doses of radiation, proinflammatory mediators recruit inflammatory cells to the damaged sites and inflamed tissues. These events are regulated by a proinflammatory transcription factor nuclear factor kappa B, which translocates to the nucleus to initiate the transcriptional activation of pro-survival factors and inflammatory cytokines. Inflammatory cytokines, namely IL-1β and tumor necrosis factor-α, which are produced upon whole-body radiation exposure, evoke systemic responses leading to tissue injury/repair[43]. IL-6 is a pleiotropic cytokine that enhances hematopoietic cell recovery following WBI when combined with G-CSF[39]. The acute inflammation following exposure to ionizing radiation must be terminated soon after resolving the injury by elevating anti-inflammatory mechanisms at the damaged area and prevent the onset of chronic inflammation and subsequent damage to tissues. The pathway analysis carried out using the RNA-seq data taken from the GEO database revealed that many of the differentially expressed genes were: *IL-1α*, *IL1-β*, *IL-6*, *CXCL3*, *CXCL5*, *CXCL8*, *CXCL2*, *CCL2*, *FLT-1*, and *IL-33* in WJ-MSCs as compared to fibroblasts (Figure 5).

When these sets of genes were further analyzed to get more insights into biological functions, cytokines and inflammatory response pathways and photodynamic-induced nuclear factor kappa B survival pathway seemed to be highly modulated (Figure 6), which was not seen in BM-MSCs and ESCs (Supplementary Figures 1 and 2). There are several reports on the beneficial role of cytokines in radioprotection. Infusion of recombinant IL-1 to mice protects against the lethal effects of ionizing radiation[44-46]. Interestingly, intravenous infusion of IL-1 and stem cell factor to mice before exposure to a lethal dose of WBI showed synergistic radioprotection[45,47,48]. CXCL5 has also been reported to play a role in the acute phase of radiation-induced salivary gland damage[49]. Bergonie and Tribondeau[50] have shown that IL-1 and tumor necrosis factor-α can induce IL-2 receptor, IL-6, colony-stimulating factor, and acute-phase proteins, which may be responsible for the observed radioprotective effects.

**CONCLUSION**

Our study showed that the co-culture of irradiated lymphocytes with WJ-MSCs protected the lymphocytes against radiation-induced cell death. Infusion of WJ-MSCs along with lymphocytes increased homeostasis-driven proliferation. Neutralization of WJ-MSC-CM with anti**-**G-CSF antibody reduced the radioprotective ability. Network biology and transcriptome profile analysis of WJ-MSCs indicated the radioprotective role of WJ-MSC-secreted cytokines. Thus, WJ-MSC-CM may be used as a therapeutic option during the recovery of radiation-exposed victims.

**ARTICLE HIGHLIGHTS**

***Research background***

Exposure to high doses of ionizing radiation is known to cause acute radiation syndrome, such as damage to hematopoietic, gastrointestinal, and neurovascular systems depending on the dose. To avoid acute radiation syndrome, regenerative therapy will be a good therapeutic option. Therefore, stem cell therapy may be one of the promising candidates to ameliorate acute radiation syndrome because of its regenerative and damage sensing potential.

***Research motivation***

Stem cells isolated from Wharton’s jelly of the umbilical cord are a unique source of mesenchymal stromal/stem cells (MSCs), which have been reported to be safe when administered to recipients without inducing any adverse effects or teratoma formation. Recently, we reported that human Wharton’s jelly-MSCs (hWJ-MSCs) and their conditioned medium (CM) have significant therapeutic radioprotective potential in lethally irradiated mice. These findings motivated us to identify a unique feature of hWJ-MSCs over other sources of stem cells for the understanding of its radioprotective mechanism and deciphering the role of the granulocyte-colony stimulating factor (G-CSF) present in hWJ-MSC-CM.

***Research objectives***

The main objective was to understand the radioprotective mechanism of soluble factors secreted by hWJ-MSCs and identification of their unique genes.

***Research methods***

Propidium iodide staining, endogenous spleen colony-forming assay, and survival study were carried out for radioprotection studies. Homeostasis-driven proliferation assay was performed for *in vivo* lymphocyte proliferation measurement. Neutralization of G-CSF with anti-G-CSF was done to investigate the role of G-CSF in therapeutic radioprotection. Analysis of RNAseq data was performed to find the unique genes of WJ-MSCs by comparing them with bone marrow mesenchymal stem cells, embryonic stem cells, and human fibroblasts. Gene enrichment analysis and protein-protein interaction network were used for pathway analysis.

***Research results***

Co-culture of irradiated murine splenic lymphocytes with WJ-MSCs offered significant radioprotection to lymphocytes. WJ-MSC transplantation increased the homeostasis-driven proliferation of the lymphocytes. Neutralization of WJ-MSC-CM with G-CSF antibody abolished therapeutic radioprotection. Transcriptome analysis showed that WJ-MSCs share several common genes with bone marrow MSCs and embryonic stem cells and express a high level of unique genes such as interleukin (*IL*)*1-α*, *IL1-β*, *IL-6*, *CXCL3*, *CXCL5*, *CXCL8*, *CXCL2*, *CCL2*, *FLT-1*, and *IL-33*. It was also observed that WJ-MSCs preferentially modulated several cellular pathways and processes that are responsible for the repair and regeneration of damaged tissues compared to other sources of stem cells. Cytokine-based network analysis showed that most of the radiosensitive tissues have a more complex network for the elevated cytokines.

***Research conclusions***

This study showed the role of cytokine G-CSF present in WJ-MSC-CM in eliciting therapeutic radioprotection. Systemic infusion of WJ-MSC-CM may have significant potential for treating accidental radiation exposed victims.

***Research perspectives***

WJ-MSC-CM holds significant therapeutic radioprotective ability and has translational potential for its use during radiation accidents.

**ACKNOWLEDGEMENTS**

The authors thank Dr. Amrita Misri and Dr. Nigamananda Mishra for their support in the project and helping in the collection of the umbilical cord. Authors also thank Ms. Binita Kumar for acquiring flow cytometry samples and Mr. Deepak Kathole and Mr. B. A. Naidu for maintaining animal and helping in animal experiments.

**REFERENCES**

1 **Bogdándi EN**, Balogh A, Felgyinszki N, Szatmári T, Persa E, Hildebrandt G, Sáfrány G, Lumniczky K. Effects of low-dose radiation on the immune system of mice after total-body irradiation. *Radiat Res* 2010; **174**: 480-489 [PMID: 20726712 DOI: 10.1667/RR2160.1]

2 **Bharti D**, Shivakumar SB, Park JK, Ullah I, Subbarao RB, Park JS, Lee SL, Park BW, Rho GJ. Comparative analysis of human Wharton's jelly mesenchymal stem cells derived from different parts of the same umbilical cord. *Cell Tissue Res* 2018; **372**: 51-65 [PMID: 29204746 DOI: 10.1007/s00441-017-2699-4]

3 **Checker R**, Patwardhan RS, Jayakumar S, Maurya DK, Bandekar M, Sharma D, Sandur SK. Chemical and biological basis for development of novel radioprotective drugs for cancer therapy. *Free Radic Res* 2021; **55**: 595-625 [PMID: 34181503 DOI: 10.1080/10715762.2021.1876854]

4 **Bentzen SM**. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. *Nat Rev Cancer* 2006; **6**: 702-713 [PMID: 16929324 DOI: 10.1038/nrc1950]

5 **Bernard ME**, Kim H, Berhane H, Epperly MW, Franicola D, Zhang X, Houghton F, Shields D, Wang H, Bakkenist CJ, Frantz MC, Forbeck EM, Goff JP, Wipf P, Greenberger JS. GS-nitroxide (JP4-039)-mediated radioprotection of human Fanconi anemia cell lines. *Radiat Res* 2011; **176**: 603-612 [PMID: 21939290 DOI: 10.1667/rr2624.1]

6 **Bernier J**, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. *Nat Rev Cancer* 2004; **4**: 737-747 [PMID: 15343280 DOI: 10.1038/nrc1451]

7 **Karp JM**, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. *Cell Stem Cell* 2009; **4**: 206-216 [PMID: 19265660 DOI: 10.1016/j.stem.2009.02.001]

8 **Bandekar M**, Maurya DK, Sharma D, Checker R, Gota V, Mishra N, Sandur SK. Xenogeneic transplantation of human WJ-MSCs rescues mice from acute radiation syndrome via Nrf-2-dependent regeneration of damaged tissues. *Am J Transplant* 2020; **20**: 2044-2057 [PMID: 32040239 DOI: 10.1111/ajt.15819]

9 **Gao Z**, Zhang Q, Han Y, Cheng X, Lu Y, Fan L, Wu Z. Mesenchymal stromal cell-conditioned medium prevents radiation-induced small intestine injury in mice. *Cytotherapy* 2012; **14**: 267-273 [PMID: 21958222 DOI: 10.3109/14653249.2011.616194]

10 **Xue J**, Li X, Lu Y, Gan L, Zhou L, Wang Y, Lan J, Liu S, Sun L, Jia L, Mo X, Li J. Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. *Mol Ther* 2013; **21**: 456-465 [PMID: 23299797 DOI: 10.1038/mt.2012.183]

11 **Chang YH**, Lin LM, Lou CW, Chou CK, Ch'ang HJ. Bone marrow transplantation rescues intestinal mucosa after whole body radiation via paracrine mechanisms. *Radiother Oncol* 2012; **105**: 371-377 [PMID: 23146318 DOI: 10.1016/j.radonc.2012.10.005]

12 **Chang P**, Qu Y, Liu Y, Cui S, Zhu D, Wang H, Jin X. Multi-therapeutic effects of human adipose-derived mesenchymal stem cells on radiation-induced intestinal injury. *Cell Death Dis* 2013; **4**: e685 [PMID: 23788042 DOI: 10.1038/cddis.2013.178]

13 **Schmoldt A**, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. *Biochem Pharmacol* 1975; **24**: 1639-1641 [PMID: 10 DOI: 10.1634/stemcells.2007-0637]

14 **Bi B**, Schmitt R, Israilova M, Nishio H, Cantley LG. Stromal cells protect against acute tubular injury via an endocrine effect. *J Am Soc Nephrol* 2007; **18**: 2486-2496 [PMID: 17656474 DOI: 10.1681/asn.2007020140]

15 **Ionescu L**, Byrne RN, van Haaften T, Vadivel A, Alphonse RS, Rey-Parra GJ, Weissmann G, Hall A, Eaton F, Thébaud B. Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. *Am J Physiol Lung Cell Mol Physiol* 2012; **303**: L967-L977 [PMID: 23023971 DOI: 10.1152/ajplung.00144.2011]

16 **Hung SC**, Pochampally RR, Chen SC, Hsu SC, Prockop DJ. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. *Stem Cells* 2007; **25**: 2363-2370 [PMID: 17540857 DOI: 10.1634/stemcells.2006-0686]

17 **Boomsma RA**, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. *PLoS One* 2012; **7**: e35685 [PMID: 22558198 DOI: 10.1371/journal.pone.0035685]

18 **Deans RJ**, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. *Exp Hematol* 2000; **28**: 875-884 [PMID: 10989188 DOI: 10.1016/s0301-472x(00)00482-3]

19 **Majumdar MK**, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. *J Hematother Stem Cell Res* 2000; **9**: 841-848 [PMID: 11177595 DOI: 10.1089/152581600750062264]

20 **Mouiseddine M**, François S, Semont A, Sache A, Allenet B, Mathieu N, Frick J, Thierry D, Chapel A. Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. *Br J Radiol* 2007; **80 Spec No 1**: S49-S55 [PMID: 17704326 DOI: 10.1259/bjr/25927054]

21 **Hu KX**, Sun QY, Guo M, Ai HS. The radiation protection and therapy effects of mesenchymal stem cells in mice with acute radiation injury. *Br J Radiol* 2010; **83**: 52-58 [PMID: 20139249 DOI: 10.1259/bjr/61042310]

22 **Sémont A**, Mouiseddine M, François A, Demarquay C, Mathieu N, Chapel A, Saché A, Thierry D, Laloi P, Gourmelon P. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. *Cell Death Differ* 2010; **17**: 952-961 [PMID: 20019749 DOI: 10.1038/cdd.2009.187]

23 **Lange C**, Brunswig-Spickenheier B, Cappallo-Obermann H, Eggert K, Gehling UM, Rudolph C, Schlegelberger B, Cornils K, Zustin J, Spiess AN, Zander AR. Radiation rescue: mesenchymal stromal cells protect from lethal irradiation. *PLoS One* 2011; **6**: e14486 [PMID: 21245929 DOI: 10.1371/journal.pone.0014486]

24 **Yang X**, Balakrishnan I, Torok-Storb B, Pillai MM. Marrow Stromal Cell Infusion Rescues Hematopoiesis in Lethally Irradiated Mice despite Rapid Clearance after Infusion. *Adv Hematol* 2012; **2012**: 142530 [PMID: 22400029 DOI: 10.1155/2012/142530]

25 **Liu Y**, Chen XH, Si YJ, Li ZJ, Gao L, Gao L, Zhang C, Zhang X. Reconstruction of hematopoietic inductive microenvironment after transplantation of VCAM-1-modified human umbilical cord blood stromal cells. *PLoS One* 2012; **7**: e31741 [PMID: 22384064 DOI: 10.1371/journal.pone.0031741]

26 **Rachakatla RS**, Marini F, Weiss ML, Tamura M, Troyer D. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. *Cancer Gene Ther* 2007; **14**: 828-835 [PMID: 17599089 DOI: 10.1038/sj.cgt.7701077]

27 **Liu S**, Yuan M, Hou K, Zhang L, Zheng X, Zhao B, Sui X, Xu W, Lu S, Guo Q. Immune characterization of mesenchymal stem cells in human umbilical cord Wharton's jelly and derived cartilage cells. *Cell Immunol* 2012; **278**: 35-44 [PMID: 23121974 DOI: 10.1016/j.cellimm.2012.06.010]

28 **Racz GZ**, Kadar K, Foldes A, Kallo K, Perczel-Kovach K, Keremi B, Nagy A, Varga G. Immunomodulatory and potential therapeutic role of mesenchymal stem cells in periodontitis. *J Physiol Pharmacol* 2014; **65**: 327-339 [PMID: 24930504]

29 **Bandekar M,** Maurya DK, Sharma D, Checker R, Gota V, Mishra N, Sandur SK. Therapeutic radioprotection by human umbilical cord derived Wharton's jelly mesenchymal stein cells: Role of cytokines and nrf‐2. *Free Radic Biol Med* 2019; **145:** S18 [DOI: 10.1016/j.freeradbiomed.2019.10.042]

30 **Maere S**, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. *Bioinformatics* 2005; **21**: 3448-3449 [PMID: 15972284 DOI: 10.1093/bioinformatics/bti551]

31 **Raudvere U**, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Res* 2019; **47**: W191-W198 [PMID: 31066453 DOI: 10.1093/nar/gkz369]

32 **Kwon SG**, Kwon YW, Lee TW, Park GT, Kim JH. Recent advances in stem cell therapeutics and tissue engineering strategies. *Biomater Res* 2018; **22**: 36 [PMID: 30598836 DOI: 10.1186/s40824-018-0148-4]

33 **Nagayama H**, Misawa K, Tanaka H, Ooi J, Iseki T, Tojo A, Tani K, Yamada Y, Kodo H, Takahashi TA, Yamashita N, Shimazaki S, Asano S. Transient hematopoietic stem cell rescue using umbilical cord blood for a lethally irradiated nuclear accident victim. *Bone Marrow Transplant* 2002; **29**: 197-204 [PMID: 11859391 DOI: 10.1038/sj.bmt.1703356]

34 **Azzam EI**, Yang Z, Li M, Kim S, Kovalenko OA, Khorshidi M, Ende N. The effect of human cord blood therapy on the intestinal tract of lethally irradiated mice: possible use for mass casualties. *Int J Radiat Biol* 2010; **86**: 467-475 [PMID: 20184442 DOI: 10.3109/09553000903567987]

35 **Ganta C**, Chiyo D, Ayuzawa R, Rachakatla R, Pyle M, Andrews G, Weiss M, Tamura M, Troyer D. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. *Cancer Res* 2009; **69**: 1815-1820 [PMID: 19244122 DOI: 10.1158/0008-5472.CAN-08-2750]

36 **Ayuzawa R**, Doi C, Rachakatla RS, Pyle MM, Maurya DK, Troyer D, Tamura M. Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. *Cancer Lett* 2009; **280**: 31-37 [PMID: 19285791 DOI: 10.1016/j.canlet.2009.02.011]

37 **Maurya DK**, Doi C, Kawabata A, Pyle MM, King C, Wu Z, Troyer D, Tamura M. Therapy with un-engineered naïve rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma. *BMC Cancer* 2010; **10**: 590 [PMID: 21029413 DOI: 10.1186/1471-2407-10-590]

38 **Matsuzuka T**, Rachakatla RS, Doi C, Maurya DK, Ohta N, Kawabata A, Pyle MM, Pickel L, Reischman J, Marini F, Troyer D, Tamura M. Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. *Lung Cancer* 2010; **70**: 28-36 [PMID: 20138387 DOI: 10.1016/j.lungcan.2010.01.003]

39 **Singh VK**, Fatanmi OO, Singh PK, Whitnall MH. Role of radiation-induced granulocyte colony-stimulating factor in recovery from whole body gamma-irradiation. *Cytokine* 2012; **58**: 406-414 [PMID: 22487481 DOI: 10.1016/j.cyto.2012.03.011]

40 **Du R**, Hu P, Liu Q, Zhang J, Deng G, Hu D, Zhang J. Granulocyte Colony-Stimulating Factor Treatment During Radiotherapy Is Associated With Survival Benefit in Patients With Lung Cancer. *Technol Cancer Res Treat* 2018; **17**: 1533033818816076 [PMID: 31122176 DOI: 10.1177/1533033818816076]

41 **Shim S**, Lee SB, Lee JG, Jang WS, Lee SJ, Park S, Lee SS. Mitigating effects of hUCB-MSCs on the hematopoietic syndrome resulting from total body irradiation. *Exp Hematol* 2013; **41**: 346-53.e2 [PMID: 23333483 DOI: 10.1016/j.exphem.2013.01.002]

42 **Yañez R**, Lamana ML, García-Castro J, Colmenero I, Ramírez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. *Stem Cells* 2006; **24**: 2582-2591 [PMID: 16873762 DOI: 10.1634/stemcells.2006-0228]

43 **Linard C**, Marquette C, Mathieu J, Pennequin A, Clarençon D, Mathé D. Acute induction of inflammatory cytokine expression after gamma-irradiation in the rat: effect of an NF-kappaB inhibitor. *Int J Radiat Oncol Biol Phys* 2004; **58**: 427-434 [PMID: 14751512 DOI: 10.1016/j.ijrobp.2003.09.039]

44 **Neta R**, Oppenheim JJ. Cytokines in therapy of radiation injury. *Blood* 1988; **72**: 1093-1095 [PMID: 2458148]

45 **Bhang SH**, Lee S, Shin JY, Lee TJ, Jang HK, Kim BS. Efficacious and clinically relevant conditioned medium of human adipose-derived stem cells for therapeutic angiogenesis. *Mol Ther* 2014; **22**: 862-872 [PMID: 24413377 DOI: 10.1038/mt.2013.301]

46 **Neta R**, Douches S, Oppenheim JJ. Interleukin 1 is a radioprotector. *J Immunol* 1986; **136**: 2483-2485 [PMID: 3512714]

47 **Neta R**, Oppenheim JJ, Wang JM, Snapper CM, Moorman MA, Dubois CM. Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 up-regulation of mRNA and protein expression for c-kit on bone marrow cells. *J Immunol* 1994; **153**: 1536-1543 [PMID: 7519205]

48 **Bertho JM**, Frick J, Prat M, Demarquay C, Dudoignon N, Trompier F, Gorin NC, Thierry D, Gourmelon P. Comparison of autologous cell therapy and granulocyte-colony stimulating factor (G-CSF) injection vs. G-CSF injection alone for the treatment of acute radiation syndrome in a non-human primate model. *Int J Radiat Oncol Biol Phys* 2005; **63**: 911-920 [PMID: 15913916 DOI: 10.1016/j.ijrobp.2005.03.045]

49 **Berry SE**. Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions. *Stem Cells Transl Med* 2015; **4**: 91-98 [PMID: 25391645 DOI: 10.5966/sctm.2014-0060]

50 **Bergonie J**, Tribondeau L. Interpretation of some results of radiotherapy and an attempt at determining a logical technique of treatment. *Radiat Res* 1959; **11**: 587-588 [PMID: 13799420]

**Footnotes**

**Institutional review board statement:** Ethical approval for isolation and conducting experiments using human Wharton’s jelly mesenchymal stem cells was obtained from the Institutional ethical review board at Bhabha Atomic Research Centre Hospital, Mumbai, India (project numbers IC-SCR-BARC/2018/2 and BARCHMEC/14).

**Institutional animal care and use committee statement:** All animal experiments were carried out according to the internationally accepted norms and principles. For conducting animal experiments, the guidelines issued by the Institutional Animal Ethics Committee of Bhabha Atomic Research Centre, Government of India, were strictly followed (BAEC/15/18).

**Conflict-of-interest statement:** The authors do not have a potential conflict of interest concerning the research, authorship, and/or publication of this article.

**Data sharing statement:** No additional data is available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** Society for Free radical Research-India.

**Peer-review started:** January 28, 2022

**First decision:** March 11, 2022

**Article in press:**

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Miceli V, Italy; Prasetyo EP, Indonesia; Shalaby MN, Egypt **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Fan JR


**Figure Legends**




**Figure 1 *In vitro* radioprotective property of Wharton’s jelly-derived mesenchymal stromal/stem cells and its conditioned medium to murine splenic lymphocytes.** Irradiated splenic lymphocytes were either co-cultured with Wharton’s jelly-derived mesenchymal stromal/stem cells (WJ-MSCs) or cultured with conditioned media collected from WJ-MSCs culture for 24 h. Cells were stained with propidium iodide, and cell death was enumerated in lymphocytes. A: Flow cytometry data along with bar graph showed therapeutic radioprotection to lymphocytes when cultured in the presence of WJ-MSCs; B: Flow cytometry data along with bar graph showed radioprotection to lymphocytes when cultured in the presence of conditioned medium. a*P* < 0.05; b*P* < 0.005 compared to radiation control. NM: Non-conditioned media; CM: Conditioned media.




**Figure 2 Role of granulocyte-colony stimulating factor in Wharton’s jelly-derived mesenchymal stromal/stem cells-conditioned medium-mediated radioprotection.** Wharton’s jelly-derived mesenchymal stromal/stem cells-conditioned medium (WJ-MSCs-CM) was neutralized with anti-granulocyte-colony stimulating factor (G-CSF) antibody and was then infused to irradiated (6 Gy or 8.5 Gy) or control mice.A: Mice were euthanized on day 15 to calculate the average spleen index. Each bar represents mean ± standard error of the mean from 5 mice; B: Bar chart showed the number of colony forming units in the spleen in different groups; C: Mice were exposed to 8.5 Gy whole-body irradiation and injected intravenously with PBS or WJ-MSC-CM or WJ-MSC-CM neutralized with G-CSF 24 h after irradiation (*n* = 12 mice *per* group) and monitored for survival; D: Plot showing changes in body weight for 30 d. a*P* < 0.05; b*P* < 0.0001 as compared to whole body irradiation. CM: Conditioned media; G-CSF Neu Ab: Granulocyte-colony stimulating factor neutralizing antibody; WBI: Whole body irradiation.





**Figure 3 Effect of Wharton's jelly-derived mesenchymal stromal/stem cells on homeostasis-driven proliferation of lymphocytes in lymphopenic mice.** Wharton's jelly-derived mesenchymal stromal/stem cells (WJ-MSCs) were mixed with carboxyfluorescein diacetate succinimidyl ester (CFSE) labeled lymphocytes were injected into 6 Gy exposed mice. In another group, only CFSE labeled lymphocytes were injected into irradiated mice. A: Dot plot shows gating strategy to monitor the proliferation of lymphocytes after acquiring the samples on flow cytometer; B: Bar graph showing % of CFSE positive lymphocytes with and without WJ-MSCs; C: Flow cytometric histograms showing lymphocyte proliferation; D: Bar graph showing percent daughter cells; E: Bar graph showing spleen index (*n* = 4 mice *per* group). a*P* < 0.05; b*P* < 0.005 as compared to radiation alone.




**Figure 4 Comparative differential gene expression analysis of stem cells (Wharton’s jelly-derived mesenchymal stromal/stem cells, bone marrow mesenchymal stromal/stem cells and embryonic stem cells) *vs* fibroblasts.** A: Bar graph showed differential gene expression among different stem cells as well as with fibroblasts. Expression Analysis Settings: Fold change in gene expression < -5 or > 5 and *P* < 0.05, Anova Method: Ebayes; B: Pie chart showed percentage of gene expression in Wharton’s jelly-derived mesenchymal stromal/stem cells (MSCs), bone marrow MSCs, and embryonic stem cells as compared to fibroblasts.WJ-MSC: Wharton’s jelly-derived mesenchymal stromal/stem cells; BMMSC: Bone marrow mesenchymal stem cells; ESC: Embryonic stem cells.





**Figure 5 Differential gene expression in Wharton’s jelly-derived mesenchymal stromal/stem cells compared to fibroblasts.** A: Bar graph showed some of the highly upregulated genes in Wharton’s jelly-derived mesenchymal stromal/stem cells (WJ-MSCs); B: Bar graph showed some of the highly downregulated genes in WJ-MSCs.


 

**Figure 6 Two of the highly modulated pathways by differentially expressed genes of Wharton’s jelly-derived mesenchymal stromal/stem cells.** A: Cytokines and inflammatory response pathway; B: Photodynamic induced nuclear factor kappa B survival pathway.WJ-MSC: Wharton’s jelly-derived mesenchymal stromal/stem cells; NF-κB: Nuclear factor kappa B; NK cell: Natural killer cell; ROS: Reactive oxygen species.










**Figure 7 Network of protein-protein interaction obtained using serum cytokines/chemokines in mice after Wharton’s jelly-derived mesenchymal stromal/stem cell infusion.** A: Extended protein-protein interaction (PPI) network was constructed using data from serum collected from mice injected with Wharton’s jelly-derived mesenchymal stromal/stem cells; B: Tissue specific extended PPI network created from the mouse serum cytokine data.





**Figure 8 Cluster analysis of the protein-protein interaction network.** Different clustered nodes and edges derived from the extended protein-protein interaction from the secreted mouse cytokine/chemokine data.